Regen BioPharma Inc (RGBP)

[kfox]

SP increases will occur with PRs that have some reasonable non dilutive financing, or revenue generating opportunity. I'm optimistic that if we get Orphan status the possibility of grant funding and a faster path to market will bring in new investors. It's worked for many but NOT ALL biotechs. Strong NCI progress may also attract investors. Of course real concrete dollars from BP would be the surest rocket fuel.

To answer your question I have seen many PRs do nothing but disappoint and the SP suffer.